A Pharmacokinetic and Pharmacodynamic Analysis of CPT‐11 and Its Active Metabolite SN‐38

Japanese Journal of Cancer Research

Volumn 86, Issue 1, 1995, Pages 101-110

  Sasaki, Yasutsuna ^a,b   Hakusui, Hideo ^c   Mizuno, Shoichi ^d   Morita, Masashige ^b   Miya, Toshimichi ^b   Eguchi, Kenji ^b   Shinkai, Tetsu ^b   Tamura, Tomohide ^b   Ohe, Yuichiro ^b   Saijo, Nagahiro ^e  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c DAIICHI SANKYO CO   (Japan)

^d Epidemiology Division ^*

^e NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

AUC; CPT 11; Pharmacodynamics; Pharmacokinetics; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DRUG METABOLITE; INDOCYANINE GREEN; IRINOTECAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG RETENTION; DRUG TOXICITY; DRUG URINE LEVEL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MULTIVARIATE ANALYSIS; NAUSEA; PHARMACODYNAMICS; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DIARRHEA; FEMALE; HUMAN; JAPAN; KINETICS; LEUKOPENIA; MALE; MIDDLE AGE; NEOPLASMS; PROSPECTIVE STUDIES; SUPPORT, NON-U.S. GOV'T;

EID: 0028813952     PISSN: 09105050     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1995.tb02994.x     Document Type: Article

References (34)

1. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibition from Camptotheca accuminata
2. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin
3. Lethal activity of camptothecin sodium on human lymphoma cell
4. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC‐100880)
5. Treatment of malignant melanoma with camptothecin (NSC‐100880)
6. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC‐100880): correlation with preclinical studies
7. Phase II study of camptothecin (NSC‐100880) in the treatment of advanced gastrointestinal cancer
8. Toxicity of camptothecin (NSC‐100880)
9. Action of 7‐ethylcamptothecin on tumor cells and its disposition in mice
10. Antitumor activity of 7‐ethyl‐10‐[4‐(1‐piperidino)‐1‐piperidino]carbonyloxycamptothecin, a novel water‐soluble derivative of camptothecin, against murine tumors
11. Establishment of a camptothecin analogue (CPT‐11)‐resistant cell line of human non‐small cell lung cancer: characterization and mechanism of resistance
12. Phase I study of weekly intravenous infusion of CPT‐11, a new derivative of camptothecin, in the treatment of advanced non‐small‐cell lung cancer
13. A phase II study of CPT‐11, a new derivative of camptothecin, for previously untreated non‐small‐cell lung cancer
14. An early phase II study of CPT‐11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma
15. Late phase II study of CPT‐11, camptothecin derivative, in advanced cervical carcinoma
16. Clinical study of CPT‐11, camptothecin derivative, on gynecological malignancy
17. Nonlinear pharmacokinetics of CPT‐11 in rats
18. Metabolism and pharmacokinetics of camptothecin analogue CPT‐11 in the mouse
19. Intracellular roles of SN‐38, a metabolite of camptothecin derivative CPT‐11, in the antitumor effect of CPT‐11
20. CPT‐11 converting enzyme from rat serum: purification and some properties
21. Toxicity and response criteria of the Eastern Cooperative Oncology Group
22. A pharmacokinetic analysis program (MULTI) for micro‐computer
23. Relationship between CPT‐11 pharmacokinetics and diarrhea in the combination chemotherapy of irinotecan (CPT‐11) and cisplatin (CDDP)
24. Phase I and pharmacology study of topotecan: a novel topoisomerase I inhibitor
25. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer
26. Pharmacological correlation between total drug concentration and lactones of CPT‐11 and SN‐38 in patients treated with CPT‐11
27. Phase I and pharmacokinetic trial of weekly CPT‐11
28. Phase I and pharmacological study of novel topoisomerase I inhibitor 7‐ethyl‐10‐[4‐(1‐piperidino)‐1‐piperidino]carbonyloxycamptothecin (CPT‐11) administered as a ninety‐minute infusion every 3 weeks
29. Therapeutic efficacy of the topoisomerase I inhibitor 7‐ethyl‐10‐(4‐[1‐piperidino]‐1‐piperidino] carbonyloxycamptothecin against human tumor xenografts: lack of cross resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9‐dimethylaminomethyl‐10‐hydroxycamptothecin
30. Phase I study of irinotecan (CPT‐11) and etoposide (E) with g‐CSF in advanced lung cancer
31. Combination phase I study of CPT‐11 (irinotecan) combined with continuous infusion of 5‐fluorouracil (5‐FU) in metastatic colorectal cancer
32. Phase I study of CPT‐11 and etoposide in patients with refractory tumors
33. Irinotecan (CPT‐11) high‐dose escalation using intensive high‐dose loperamide to control diarrhea